Vineti expands its platform to support provision of American Red Cross allogeneic apheresis collections for cellular therapy

Vineti’s technology platform for next-generation therapies will further extend the essential presence of the Red Cross in patient care

Print
| Source: Vineti

SAN FRANCISCO, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vineti, Inc., the leading software and analytics company for cell and gene therapies, today announced that it will be expanding its technology platform to support the provision of American Red Cross allogeneic apheresis collections for cellular therapy. The Red Cross, the nation’s largest single provider of blood products, is already a key provider of autologous apheresis collection services for cellular therapy.

The Vineti digital platform supports next-generation therapies by integrating and tracking the entire cell therapy process, from ordering and logistics to manufacturing and clinical data.

This technology will help the Red Cross expand patient access to cell therapy products and set standards for this emerging field.

“We developed the Vineti platform to help innovative treatments reach the patients who need them the most. We strongly believe that the right leaders, setting standards early in this new field, will create an essential environment of patient safety and trust,” said Amy DuRoss, CEO at Vineti. “Vineti is proud to provide this service to the Red Cross to expand patient access to these critical therapies.”

With multiple fixed sites across the country and staff experienced in apheresis collections, the Red Cross is exceptionally well-positioned to provide cell collection services to biotechnology and pharmaceutical companies.

“The Red Cross has been involved in performing apheresis collections in support of cellular therapy for over ten years, and currently performs thousands of such procedures each year,” said Geoff Kaufmann, Vice President of Patient Services at the Red Cross. “Access to a technology platform to support allogeneic collections will enhance our cellular therapy offerings.”

Vineti’s configurable, cloud-based platform improves cell and gene therapy product performance overall, promotes regulatory compliance, and enables faster, safer, broader access for patients. Caregivers, suppliers, and pharmaceutical pioneers are empowered to reach more patients sooner by partnering their products and therapies with a digital, data-driven platform focused on scalability, efficiency and safety.

The Vineti platform is available directly from Vineti. Patients, clinicians, suppliers, and pharmaceutical developers can learn more at www.vineti.com.

About Vineti, Inc.

Vineti is the first commercial cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of 21st century medicine. The Vineti platform integrates logistics, manufacturing and clinical data to improve product performance overall. Caregivers and pharmaceutical pioneers are empowered to help more patients more effectively and safely, treatments are better understood and improved over time, and most importantly, there’s an opportunity to provide greater health outcomes—and cures—to patients in need. For more information, please visit www.vineti.com.  Sign up to follow @vinetiworks on https://twitter.com/vinetiworks.

NOTE: Vineti and the Vineti logo are trademarks of Vineti , Inc. All other trademarks and service marks are the property of their respective owners. 

Media Contact:
Kaustuva Das
Thermal PR for Vineti
415-659-1970
kdas@thermalpr.com